Although most of the melanomas that harbor BRAF mutations respond dramatically to treatment with BRAF inhibitors, nearly all develop resistance to the drugs in less than a year, and previous studies showed that melanomas alter a cell signaling pathway called the MAPK pathway to become resistant.

More...